Revenue was driven by base revenue growth of 4.2% as reported, 8.6% currency-neutral.
Medical segment sales increased 5.8% Y/Y to $2.38 billion.
Life Sciences segment sales declined 15.9% Y/Y to $1.29 billion, reflecting the decline in COVID-only testing revenues.
Interventional segment revenues grew 2.4% Y/Y to $1.09 billion.
Operating income increased from $380 million to $490 million, with the margin improving from 7.8% to 10.3%.
Adjusted EPS of $2.75, up from $2.15 a year ago, topping the consensus of $2.74.
Guidance: BD expects FY23 sales of $18.6-$18.8 billion versus the consensus of $19.37 billion.
Revenue guidance assumes base business currency-neutral revenue growth of 5.25%-6.25% and approximately $125-$175 million in COVID-19-only diagnostic testing revenues.
The foreign exchange would represent a reduction of approximately 450 basis points to total company revenue growth.
The company expects adjusted EPS of $11.85-$12.10 versus the consensus of $12.19.
Price Action: BDX shares closed lower by 0.55% at $218.29 on Wednesday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.